At a glance
- Several lab properties in Manhattan and the surrounding boroughs have traded at a loss this year, often to landlords from outside the life sciences sector, Commercial Observer reported.
- For allocators holding New York lab exposure, the sale implies about $365 per planned square foot, or $73 million for the 200,000 square feet Taconic had planned.
- Savills' third-quarter report put citywide lab vacancy at 22.8%, down from 32.5% in the second quarter, a decline the brokerage attributed to recent sales.
Taconic Partners sold its planned Iron Horse Labs site at 309 East 94th Street to multifamily developer LCOR for $73 million in September, ending plans for a 200,000-square-foot Class A research lab.
Several lab properties in Manhattan and the surrounding boroughs have traded at a loss this year, often to landlords from outside the life sciences sector, Commercial Observer reported. The Iron Horse parcel went to an apartment builder instead.
For allocators holding New York lab exposure, the sale implies about $365 per planned square foot, or $73 million for the 200,000 square feet Taconic had planned. That is a benchmark to hold against a fund's carrying value on a New York lab asset.
"New York's life sciences real estate market is in a really early stage of stabilization," said Victor Rodriguez, CoStar's senior director of analytics. "I wouldn't call this a recovery, by any stretch," he said.
Savills' third-quarter report put citywide lab vacancy at 22.8%, down from 32.5% in the second quarter, a decline the brokerage attributed to recent sales. Inventory stood at 3.1 million square feet.
A national report from JLL in June ranked New York City's life sciences availability rate highest in the country, at 37%.
"New York was just ripe for overdevelopment," said Jonathan Schifrin, Savills' senior managing director and life sciences lead in New York. Private-sector demand, largely from early-stage startups, weakened after 2021, though the city's smaller market compared with Boston saw less dramatic drops in rent. The macro changes "pulled the rug out from under New York," he said.
Savills' October research, as Private Wealth Daily previously reported, put Boston's life sciences vacancy at 28.1%, above New York's 22.8%.
The sale implies about $365 a planned square foot
Sale price and planned lab space behind the per-square-foot benchmark, Sept. 2026
Sale price
$73M
Planned lab space
200,000 sf
$73 million divided by 200,000 planned square feet is about $365 per square foot.
I wouldn't call this a recovery, by any stretch.Victor Rodriguez, CoStar's senior director of analytics
Reported by the Sectors desk from Commercial Observer and Private Wealth Daily archive. Published . Corrections